meaningful use workgroup new pathways for meaningful use stage 3

44
Meaningful Use Workgroup New Pathways for Meaningful Use Stage 3 April 9, 2013 Paul Tang, MD George Hripcsak, MD Christine Bechtel 1

Upload: adler

Post on 06-Jan-2016

60 views

Category:

Documents


4 download

DESCRIPTION

Meaningful Use Workgroup New Pathways for Meaningful Use Stage 3. April 9, 2013 Paul Tang, MD George Hripcsak , MD Christine Bechtel. Agenda. Review of HITPC presentation and feedback Consolidation and Deeming Clinical Documentation - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

1

Meaningful Use Workgroup New Pathways for Meaningful Use Stage 3

April 9, 2013Paul Tang, MD

George Hripcsak, MDChristine Bechtel

Page 2: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

2

Agenda

• Review of HITPC presentation and feedback– Consolidation and Deeming– Clinical Documentation

• Comments/discussion of direction from HITPC and directional decisions (to be fleshed out in subgroups

• Work plan review• Reconcile RFC comments where divergent public

comments

Page 3: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

3

Presentation to HITPC Meaningful Use Workgroup

April 3, 2013

Page 4: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Stages of Meaningful UseImproving Outcomes

Stage 1: Data capture and patient access

Stage 2: Information exchange and care coordination

Stage 3: Improved outcomes

Stage 12011-13

Stage 22014-15

Stage 32016-17

4

Page 5: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Stages of Meaningful UseImproving Outcomes

Stage 1: Data capture and patient access

Stage 2: Information exchange and care coordination

Stage 3: Improved outcomes

Stage 12011-13

Stage 22014-15

Stage 32016-17

5

Page 6: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

6

Original Principles for Stage 3 Recommendations

• Supports new model of care (e.g., team-based, outcomes-oriented, population management)

• Addresses national health priorities (e.g., NQS, prevention, Partnerships for Patients, Million Hearts)

• Broad applicability (since MU is a floor)– Provider specialties (e.g., primary care, specialty care)– Patient health needs– Areas of the country

• Not "topped out" or not already driven by market forces• Mature standards widely adopted or could be widely adopted

by 2016 (for stage 3)

Page 7: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

7

Lessons from Stages 1Implications for Stage 3

Stage 1 Experience• Substantial increase in adoption

rates and effective use• Mandatory floor creating network

effects• Thresholds consistently exceeded

• Consistent use across the years

• Reporting requirements have considerable costs and burden

• Prescriptive, “forced march” impacts available resources for innovation or to address local priorities

Implications for Stage 3• Creating critical mass of users and

data in electronic form• Rising tide is floating boats (e.g.,

setup for patient engagement, HIE)• Once MU functionality is

implemented, it is used• Gains from stage 1 (and 2) will persist• Stage 3: Simplify and reduce

reporting requirements• Stage 3: Rely more heavily on market

pull (e.g., new payment incentives); promote innovative approaches ie., reward good behavior

Page 8: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

8

Additional Goals for Stage 3

• Address key gaps (e.g., interoperability, patient engagement, reducing disparities) in EHR functionality that the market will not drive alone, but are essential for all providers:– to create level playing field– to create network effects– to fulfill need for a public good

• Consolidate MU objectives where higher level objective implies compliance with subsumed process objectives

• Consider alternative pathway where meeting performance and/or improvement thresholds deems satisfaction of subset of relevant MU functionality implicitly required to achieve performance/improvement

Page 9: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Consolidation Subgroup

Christine Bechtel, Chair

9

Page 10: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

10

Consolidation Summary

• 43 MUWG objectives proposed in stage 3 RFC • Consolidated to 25 objectives• Assumptions– The full WG will consider RFC feedback and update criteria– All criteria will be included in certification• Focus on advanced uses–ex: recording data vs. use data

• Give credit for MU objectives that should be standard of practice once passed stages 1 and 2 • Identify what needs to be “used” and certified

Page 11: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

11

Types of Consolidation

• Advanced within concept of another objective• Duplicative concepts– objective becomes certification only

• Demonstrated use and can trust that it will continue

Page 12: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

12

Advanced within Concept of Another Objective

Patient preferred means of communication (SGRP208)

DemographicsAdded as an additional element

Patient education, per patient preference

Clinical Summary, per patient preference

Certification Criteria

Maintained Objective

Key:

Reminders, per patient preference

Page 13: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

13

Duplicative Concepts

Immunization intervention (SGRP401B)

CDS (113)Interventions include preventative care for

immunizations

Certification Criteria

Maintained Objective

Key:

Structured lab results (SGRP114)

Included in care summary (303)

Included in view, download, transmit (204A)

Page 14: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

14

Demonstrated Use

• Patient lists and dashboards (SGRP115)– Needed for population management and quality

measurement– How to measure use?– Existing external drivers that will drive use (new

models of care)• PQRS, value based purchasing, ACOs

Page 15: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

15

CPOE - Advanced within concept of another objective, duplicative concept, demonstrated use

CPOE for Medication Orders

Needed to provide meds within care summary (303)

Needed to provide meds within VDT (204A)

Needed for eRx formulary and generic substitutions

Certification Criteria

Maintained Objective

Key:

Page 16: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

16

Consolidation at a Glance

Page 17: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

17

Consolidation Overview

Reconciliation

eRx – formulary

CDS

Pt list/dashboard

Reminders

EH: eMAR

EH: Lab results EP

PGHD

Clinical summary

Patient education

Secure MessagingNotify of health event

Care plan*

Immunization registry

Adverse event*

Case reports to PHA

VDT ToC – Care summary

Advanced directive

Registries

Synd Surveillance

ELR

Identify clinical trials

Quality, safety, reducing health disparities

Referral loop

Test tracking

Imaging results

Electronic notes

Engaging patients & families

Improving care coordination

Population & public health

eRx transmission

Certification Criteria

Maintained Objective

Key:

* Proposed for future stage of MU

Demographics

CPOE - meds

CDS for immun

Comm preference

CPOE - rad

CPOE - lab

Amendment

Family Hx

Prob, med, allg list

Structured lab

VitalsSmoking status

Comm preference

Comm preference

Cancer registry

Specialty registry

HAI reportsDemographics

Amendment

Family Hx

Prob, med, allg list

Structured lab

VitalsSmoking status

CPOE - referrals

Inter prob list*

RxHx PDMP*

CPOE - meds

Page 18: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

18

Deeming Subgroup

Paul Tang, Chair

Page 19: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

19

Deeming Assumptions

• Cannot reliably achieve good performance (or significantly improve) without effective use of HIT

• Therefore: in order to promote innovation, reduce burden, and reward good performance, deem high performers (or significant improvers) in satisfaction of a subset of MU objectives as an optional pathway to qualifying for MU

Page 20: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

20

Example Criteria for Deeming for EPs• Demonstrate high (top 30 %ile) or improved performance (20% reduction

of gap between last year's performance and top quartile). Select two items from each of the categories below: – Prevention of high priority diseases (pick 2 from)

• Breast cancer (mammography screening)• Colon cancer (colonoscopy screening)• Influenza (flu vax)• Pneumonia (pneumococcal vaccine)• Obesity (BMI screening and follow up)• Cardiovascular disease (LDL screen)• HTN (BP screen and follow up)

– Control of high priority chronic health conditions (pick 2 from)• HTN (BP control or improvement)• Diabetes (A1c control)• Heart attack (LDL control)• Asthma (controller med)• CHF (ACEI or ARB meds)• MI (beta blocker)

Page 21: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

21

Example Criteria for Deeming for EHs• Demonstrate high (top 30 %ile) or improved performance (20% reduction

of gap between last year's performance and top quartile) for all of the below:– Patient safety (pick 2 from)

• Clostridium difficile Infection (outcome measure)• Catheter-Associated Urinary Tract Infection (outcome measure)• Central Line-Associated Blood Stream Infection (outcome measure)• MRSA (outcome measure)• Specific Surgical Site Infection (SSI) Outcome Measure• Severe sepsis and septic shock: Management bundle• Late sepsis or meningitis in very low birth weight (VLBW) neonates (risk-

adjusted)• Measure of pressure ulcers

– Care coordination (pick 2 from)• Experience of care (from HCAHPS)?• Hospital-wide-all-cause unplanned readmission measure (HWR)• CTM-3, 3-item care transition

Page 22: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

22

Additional Requirement

• Disparities– Stratify all four population reports by disparity

variables

Page 23: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

23

Deemed MU ObjectivesDeemed in Satisfaction of:• CDS• eRx – formulary, generic subs• Reminders• Electronic notes• Test tracking• Clinical summary• Patient education• Reconcile problems, meds, allergies

• *View, download, transmit (VDT), consider adding if stage 2 reports good uptake

• *Secure patient messaging, consider adding if stage 2 reports good uptake

Remaining Items:• Advance directive• eMAR• Imaging results• EH: provide lab results• Patient generated data• *VDT• *Secure patient messaging• Care summary • Care plan• Referral loop• Notification of health event• Immunization registry• ELR• Case reports to PHA• Syndromic surveillance• Reporting to 2 registries• Adverse event reporting

Page 24: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

24

Additional Considerations

• Propose performance reporting period to be 6 months vs. 1-year MU reporting period to give providers a chance to deem yet still have time to resort to functional objectives qualification if not meeting deeming thresholds

• Specialists may have fewer options for deeming as determined by available NQF QMs. If not able to report on at least 4 performance measures, then may not be eligible for the deeming pathway

Page 25: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

25

HITPC Comments• Fazard

– While it makes sense to use outcome measures, there may be measures that fall short of total outcomes, but are still closer to outcomes than functional measures. Examples: closing the referral loop, medication safety (functional measures around CPOE), patient experience (maybe pt ed is consolidated). Measures that relate to the functionality, that push further than the functional measure.

– Need to tie deeming measures to the functional measures that they relate to – Supportive in general. Encouraged to be even bolder related to consolidation - deeming with a focus on justification

for why it is appropriate to HIT. There is room for more reflection• Terry Cullen/Fazard/Christine

– Publish constraints within recommendations in terms of what would qualify for measures. Strategically involve the boards? This is an HIT program related to outcomes – innovation related to HIT?

– How big of a door will be open? ACOs, PCMH deeming? CAHPS, could be useful for providers (accessible through HIT program). Expectations that HIT incentives be spent on HIT and not duplicate other quality incentive programs. Potential to explore HIT CAHPS model – more valuable for the provider to know if the display of information is helpful for patients, hold accountable for what directly relates to MU (group not individual level).

• Gayle– Participants in the PQRS program are able to deem 2014 CQMs, is there a possibility to do the same for functional

measures? • Robert Tagalicod

– Would be ideal to align multiple programs and report once for a number of initiatives. The simpler the better. PQRS is a good starting point. Recommended working with Kate Goodrich.

– Are there unintended consequence? What level and balance is needed? • Terry Cullen

– Slide 20 (within this deck) - none of the other measures are included in core. – Slide 21 (within this deck) – none of the measures are on 2014 measure list (might be hard to improve if all new

measures).

Page 26: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

26

HITPC Comments - Specialists

• Marc Probst– Ensure not skewing to one provider group. – Paul response, followed the national priorities. Supportive.

• Chris– The role of the patient registries going forward? Reporting to a professional registry could be consolidated, way for using reports.

Collaboration with specialty societies. Specialty societies are using registries too.• Judy Faulkner

– Are there more things for pediatrics?• Gayle

– To develop some of the categories for deeming – reach out to specialty societies to come up with recommendations and put together a package for deeming?

• David Lansky– Invite specialists to propose measures which would lend themselves for deeming. Challenge is to define criteria for what measures would

qualify that they leverage IT infrastructure, information flow and management. Continue to encourage vendors to create more flexible means for reporting. Measures proposed can help vendors move towards more flexible reporting platforms and enable standardization. Opportunity for measures to be used widely for public purposes, not just local narrow interests. Paul: raise the incentives for participation – reasons why outcome measures are important. Add to incentive. Christine: timing issues

• Art Davidson– Need to find a way for specialists to participate in the deeming process. Patient reported outcomes in data to registries, how does that affect

the way that the registry is used. • Neil Calman

– Too prescriptive for specialists, need to give people an opportunity to innovate in this space. Think about ways to do this for what is important to the specialty. Need to get outside of the top 10 list. Measures are being developed from those who are innovating in a field, creative things in specialty areas – how to recognize within MU?

– PT response: limited set of measures, focused on outcome measures that demonstrate control. – CB response: specialists could do consolidated approach and innovative pathway (create a measure and provide specifications to CMS to fill the

gaps).

Page 27: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

27

Clinical Documentation Presentation to HITPC

Page 28: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Clinical Documentation HearingFebruary 14, 2013

• The Future State of Clinical Data Capture and Documentation, AMIA

• Role of Clinical Documentation for Clinicians• Role of Clinical Documentation for Care Coordination

across the Health Team• Role of Clinical Documentation for Secondary Uses• Role of Clinical Documentation for Legal Purposes

28

Page 29: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Hearing Summary (I)

• Clinical documentation serves multiple stakeholders for primary and secondary uses.

• Preoccupation of billing uses may interfere with clinical use of the documentation. Legal requirements ("if it is not documented, it did not happen") also drive documentation behaviors

• Productivity tools developed (including, templates, cut/paste, copy forward, macros, etc.). Overuse or inappropriate use of these productivity tools has resulted in a concern about accuracy of the documentation and has made it difficult to find the important information

• Little quantitative, available evidence on accuracy of documentation or how to assess for good documentation

• Anecdotes about poor documentation• No clear method associated with high quality documentation => don't

prescribe just one method or prevent other methods

29

Page 30: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Hearing Summary (II)• Quality of note not necessarily associated with quality of care• Voice recognition is efficient, but does not work for everyone• Natural language processing may be useful to get structured concepts out

of free text• In order to balance the richness contained in free text with the value of

coded information, may need to use hybrid of both text and structure. Voice recognition + natural language processing + guideline-based structured templates may be used

• Sharing notes with patients for viewing may help improve accuracy of notes => decrease fraud

• Very hard to capture medical record in a dynamic EHR; cannot reduce to paper printout

• Some excessive or inappropriate documentation is due to misunderstanding of E&M coding criteria

• Ensure that vendors have security provisions that comply with requirements of "legal medical record" (e.g., data integrity, data provenance)

30

Page 31: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Recommendations (I)

1. Move clinical documentation menu item to core in stage 3– HTIPC: Need to distinguish the differences in the types of

documentation (EPs and EHs).2. Do not prescribe or prohibit method of clinical documentation. Guide

appropriate use through education and policies3. Help reader assess accuracy and find relevant changes by making the

originating source of sections of clinical documents transparent. Analogous to "track changes" in MS Word™ – HITPC: This should only relate to progress note, not the progress

note copied or pulled in– Default view of documents in the medical record and those

transmitted to other EHRs is a "clean copy" (i.e. not showing tracked changes). The reader can easily click a button and view the tracked-changes version.

31

Page 32: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Recommendations (II)4. To improve accuracy, to improve patient engagement, and to guard against fraud (HITPC: careful with

this word), EHRs should have the functionality to provide progress notes as part of MU objective for View, Download, and Transmit – – It is being done at the VA as part of bluebutton (positive experience, provider education needed

– more sensitive about what they write), hold off on adding as a use requirement for MU?– Maintaining the functionality component and as we go through RFC, haven’t been specific about

how. Differentiate between EP and EH?5. Further innovation and research required to collect and meaningfully display information (possibly using

graphical views), rather than just text 6. Increase education about E&M coding criteria; better yet, as payment reform emphasizes outcome over

transactions, seek to change E&M coding criteria to reduce over- reliance on specific language in clinical documentation

7. Propose that HITSC review what standards are needed to ensure that CEHRT maintains legal medical record content for disclosure purposes (e.g. what was accessed during the encounter and what gets printed out as the legal medical record?) – what was in the record as of a date? Remind the standards committee to review testimony.

Chad’s remarks in transcript. Standards are important8. New recommendation, Fazard: Productivity tools that don’t have a true function? Tools for upcoding

– example of something that encourages inappropriate use of documentation. – Neil: Anti-certification requirement? No clinical benefit. CMS guidance is based upon medical

necessity.

32

Page 33: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

33

MU Workgroup – Next Steps

• Workplan– Finalize consolidation and deeming proposals (use

scheduled subgroup time for consolidation and deeming subgroup meeting)

• April 30 – MU WG– Finalize consolidation and deeming approach– Review of objectives with divergent public comments

• May 14 – MU WG?• May 28 – MU WG– Subgroups present reconciled RFC comments with

consolidated MU objectives to MU WG

Page 34: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

34

Consolidation Follow-up

Page 35: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

35

Consolidation - VDT

Stage 2 VDT elements Consolidation● Patient name.● Provider's name and office contact information.● Current and past problem list.● Procedures.● Laboratory test results.● Current medication list and medication history.● Current medication allergy list and medication allergy history.● Vital signs (height, weight, blood pressure, BMI, growth charts).● Smoking status.● Demographic information (preferred language, sex, race, ethnicity, date of birth).● Care plan field(s), including goals and instructions, and any known care team members including the primary care provider (PCP) of record.An EP can make available additional information and still align with the objective. In circumstances where there is no information available to populate one or more of the fields previously listed, either because the EP can be excluded from recording such information (for example, vital signs) or because there is no information to record (for example, the EP may have an indication that the information is not available and still meet the objective and its associated measure).

● Amendments● Family history● Problems, meds, allergies (already removed)● Structured labs● Vitals● Smoking status● Demographics

Page 36: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

Consolidation – Care Summary

36

Stage 2 Care Summary Consolidation Must include the following information if the provider knows it:● Patient name.● Referring or transitioning provider's name and office contact information (EP only).● Procedures.● Encounter diagnosis● Immunizations.● Laboratory test results.● Vital signs (height, weight, blood pressure, BMI).● Smoking status.● Functional status, including activities of daily living, cognitive and disability status● Demographic information (preferred language, sex, race, ethnicity, date of birth).● Care plan field, including goals and instructions.● Care team including the primary care provider of record and any additional knowncare team members beyond the referring or transitioning provider and the receiving provider.● Discharge instructions (Hospital Only)● Reason for referral (EP only)In circumstances where there is no information available to populate one or more of the fields listed previously, the EP, eligible hospital or CAH may leave the field(s) blank and still meet the objective and its associated measure. All summary of care documents used to meet this objective must include:● Current problem list (Providers may also include historical problems at theirdiscretion)● Current medication list, and● Current medication allergy list.An EP or hospital must verify these three fields for current problem list, current medication list, and current medication allergy list are not blank and include the most recent information known by the EP or hospital as of the time of generating the summary of care document.

● CPOE for referrals● Family history● Problems, meds, allergies (already removed)● Structured labs● Vitals● Smoking status● Demographics

Page 37: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

37

Proposed Full Workgroup - RFC Discussion Items

• Demographics - 104• CDS – 113• Electronic notes - 120• VDT – 204A• PGHD – 204B• Care Summary - 303• Care Plan – 304

Page 38: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

38

Demographics – SGRP104 (I)

Stage 3 Recommendations Proposed for Future Stage Questions / CommentsRetire prior demographics objective because it is topped out (achieved 80% threshold).Certification criteria: • Occupation and industry codes• Sexual orientation, gender identity (optional fields) • Disability status • Differentiate between patient reported &

medically determined • Need to continue standards work

Do commenters agree with retiring the measure, or should we continue this objective? Continuing the measure would mean an additional number of objectives that providers will need to attest to.

Page 39: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

39

Record Demographics: 337 comments

•Commenters suggested a number of additional data elements to require/collect: Housing status (4), organ donor status (2), school lunch status, fertility status, marital status, place of birth, veteran status, hobbies and interests (2), number of guns in the household, and a variety of end-of-life care measures.•Some commenters requested more specificity on race/ethnicity data collection, including using ACA section 4302 and >7 'Asian' and >4 'native Hawaiian/islander' categories.Certification criteria: Occupation and industry codes (192 comments)•Summary: Commenters overwhelmingly support adding these, but many expressed concern about coding and standards.•Some expressed agreement with the addition for certification criteria, but would like there to be a use case so that practices actually capture this information.•A few commenters opposed these data elements, who were not sure of how relevant or useful the data would be to care, and one association, which contended that I/O data "do not bear enough relevance to a patients’ ongoing eye care" and thus oppose inclusion•Commenters expressed some concern about the cost of maintaining I/O data, of updating EHR systems to capture it, and the complexity of system development•A few commenters requested clarification on the data standards to be used, if I/O would be two fields or one or more, and the feasibility of collecting sufficiently detailed information•A couple commenters discussed including dates and keeping a longitudinal record – and note the need to distinguish 'usual' versus current occupation

Demographics - SGRP104 (II)

Page 40: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

40

Record Demographics: 337 comments

Sexual orientation, gender identity (optional fields) •Summary: Most commenters agreed with inclusion, but want more specificity as to data standards, definitions (e.g., "more than two genders"), and whether/how the data will affect other parts of EHR systems. One commenter offered detailed training suggestions to address providers' discomfort with the subject (0545)•A large number supported inclusion and recommended that they be mandatory and/or included as a use case, not just certification criteria. Some opposed inclusion and expressed discomfort with or concern about the sensitivity of the subject.•A number of those opposed did not believe these data to be relevant to care•A few did not feel that these data should be demographics, because front desk staff usually collect that and this sort of 'sensitive' data should be collected by members of the care team. •EHR vendors and provider organizations expressed concern about the complexity of development for these elements, see EHRA. Disability status •Summary: There were only a few comments on this element, but they were broadly supportive. However, commenters did raise a number of concerns, particularly concerning the availability and viability of data standards, provider burden, EHR development/upgrade cost, and relevance to practice.•The American College of Occupational and Environmental Medicine (ACOEM) would prefer that we use the term "functional status" or "workability."•Some commenters felt this element should be in clinical, not demographic data, and were concerned about increasing provider burden •Some commenters expressed concern about the standard readiness, technical costs of developing this, and upgrade costs. A number suggested that ONC collaborate with NCHS/NCBDDD to determine data standards.

Demographics - SGRP104 (III)

Page 41: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

41

Demographics - SGRP104 (IV)HITSC Feedback

• Although a high level of demographic data recording has been achieved, discontinuing the requirement could diminish collection of foundational data. Sensitive data such as sexual orientation and disability status should be omitted.

• No other sector would consider 80% to be optimal performance on an important quality measure, nor should healthcare.– Agree with the retirement of the topped out measures (Original demographic measures)– Agree with the addition of the new updated demographic measures– Structured data will be captured and not codified data at this time– What is the definition of Disability Status? Federal definition or patient identification, or otherwise– Question on how sexual orientation will or can be codified– Introduce as a general comment about Disability status being included as long as it can be

captured– Date of disability status and inclusion of functional status should be included– Note: CMS has established HCPCS and modifier coding requirements for reporting functional

status and degree of impairment for therapy services claims, and explicitly requires them to be documented into the medical record. Any CMS requirement for that kind of information for meaningful use Stage 3 should take that into account and leverage it at least where the two requirements overlap – not impose additional requirement. The CMS claims requirement impacts all manners of therapy services providers including hospitals and physicians

Page 42: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

42

Background Slides

Page 43: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

43

Stage 2 – Option 2 for reporting CQMs

• Submit and satisfactorily report CQMs under the PQRS's EHR Reporting Option.• Under this option, Medicare EPs who participate in both the PQRS and the Medicare EHR Incentive Program

will satisfy the CQM reporting component of meaningful use if they submit and satisfactorily report PQRS CQMs under the PQRS's EHR reporting option using CEHRT. – EPs choosing to report under this option for purposes of the Medicare EHR Incentive Program will be

subject to the reporting periods established for the PQRS EHR reporting option, which may be different from their EHR reporting period for the meaningful use objectives and measures. For example, in CY 2014, an EP who is beyond his or her first year of meaningful use will have a 3-month quarter EHR reporting period for the meaningful use objectives and measures, but the reporting periods for the PQRS EHR reporting option that fall within CY 2014 would apply for purposes of reporting CQMs.

– EPs who are in their first year of demonstrating meaningful use in the year immediately preceding a payment adjustment year cannot choose this Option 2 for reporting CQMs for the EHR Incentive Program. For purposes of avoiding a payment adjustment, they must submit their CQM data by attestation no later than October 1 of such preceding year.

• Regardless of whether an EP chooses Option 1 or Option 2 for CQM reporting, all EPs must also report the meaningful use objectives and measures through attestation, as well as meet all other meaningful use requirements. We acknowledge that under the PQRS, only Medicare patient information is submitted. In general, our preference is to measure quality at the all patient level, based on samples of all patient data (that is, patients that meet the denominator criteria of each reported CQM). We believe this provides a better assessment of overall care quality rendered by EPs.

Medicare and Medicaid EHR Incentive Program Final Rule p. 54057

Page 44: Meaningful Use Workgroup  New Pathways for Meaningful Use Stage 3

44

Clinical Data Registry

• SATISFACTORY REPORTING MEASURES THROUGH PARTICIPATION IN A QUALIFIED CLINICAL DATA REGISTRY.— For 2014 and subsequent years, the Secretary shall treat an eligible professional as satisfactorily submitting data on quality measures under subparagraph (A) if, in lieu of reporting measures under subsection (k)(2)(C), the eligible professional is satisfactorily participating, as determined by the Secretary, in a qualified clinical data registry (as described in subparagraph (E)) for the year.

• http://www.gpo.gov/fdsys/pkg/BILLS-112hr8enr/pdf/BILLS-112hr8enr.pdf